Recently approved worldwide by regulatory agencies (including ANVISA and FDA), the 2nd generation drug-eluting stent (DES) XienceTM (Abbott Laboratories, Abbott Park, IL, USA) combines an ultra-thin cobalt-chromium platform and a potent sirolimus-analog anti-proliferative drug, everolimus, carried by a biocompatible durable polymer. In the present review, the authors summarize the main findings of the preliminary randomized clinical trials that resulted in the approval of this new DES for clinical use and present the next studies planned with the XienceTM stent.
Drug-eluting stents; Sirolimus; Randomized controlled trial
